Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Recruiting
99 years or below
All
Phase N/A
100 participants needed
1 Location

Brief description of study

Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find effective therapies for pancreatic cancer. The platform will rapidly and efficiently test multiple novel drugs and combinations compared to standard of care therapy in first and second metastatic patients. Bayesian response-adaptive randomization will be used to assign patients to arms based on their performance in subtypes of the disease

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic Pancreatic Cancer,Pancreatic Cancer,Cancer
  • Age: 99 years or below
  • Gender: All

Age ≥ 18 years Male and Female Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (PDAC)

Updated on 04 Aug 2024. Study ID: 842508

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center